Equities analysts expect arGEN-X BV (NASDAQ:ARGX) to post sales of $8.56 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for arGEN-X BV’s earnings, with the lowest sales estimate coming in at $7.35 million and the highest estimate coming in at $9.35 million. The firm is scheduled to report its next earnings report on Monday, January 1st.
On average, analysts expect that arGEN-X BV will report full year sales of $29.88 million for the current year, with estimates ranging from $19.66 million to $39.36 million. For the next year, analysts expect that the company will post sales of $27.24 million per share, with estimates ranging from $15.27 million to $39.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover arGEN-X BV.
Several analysts recently commented on the company. JMP Securities boosted their price target on arGEN-X BV from $74.00 to $87.00 and gave the stock an “outperform” rating in a research report on Monday, January 29th. Zacks Investment Research cut arGEN-X BV from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. SunTrust Banks assumed coverage on arGEN-X BV in a research report on Sunday, April 8th. They set a “buy” rating and a $125.00 price target for the company. Finally, Piper Jaffray boosted their price target on arGEN-X BV to $100.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. arGEN-X BV presently has a consensus rating of “Buy” and a consensus price target of $86.00.
Shares of ARGX opened at $84.50 on Friday. arGEN-X BV has a one year low of $17.33 and a one year high of $87.00.
TRADEMARK VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/17/argen-x-bv-argx-expected-to-post-quarterly-sales-of-8-56-million.html.
About arGEN-X BV
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Get a free copy of the Zacks research report on arGEN-X BV (ARGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with MarketBeat.com's FREE daily email newsletter.